The influence of sequence variations in factor VII, γ -glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement

摘要: The degree of interpatient variability in the warfarin dose required to achieve desired anticoagulant response can only partly be explained by polymorphisms CYP2C9 gene, suggesting that additional genetic factors such as genes involved blood coagulation may influence requirement. In total, 165 Caucasian outpatients on stable maintenance treatment previously genotyped for were analysed common FVII, GGCX and VKORC1 genes. -402G > A polymorphism a variable number repeats intron 7 FVII gene did not significantly dose. mean doses increased with (CAA) but differences significant CYP2C9*1/*1 subgroup patients (p = 0.032). Common (6484C T) 1 led lower requirement; means 5.70 (95% C.I. 4.95-6.45), 3.49 (3.07-3.90) 2.11 (1.80-2.42) mg/day 6484 CC, CT TT genotypes, respectively 3'UTR theVKORC1 higher 3.09 (2.58- 3.60), 4.26 (3.69-4.82) 5.86 (4.53-7.19) 9041 GG, GA AA < 0.001). With regression model we 60.0% dose, which was due (CYP2C9, VKORC1), age body-surface-area. When aiming individualised therapy, at least should included predictive genotyping besides CYP2C9.